We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+30.14%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$415M
AUM Growth
-$1.65M
Cap. Flow
-$44.5M
Cap. Flow %
-10.72%
Top 10 Hldgs %
57.35%
Holding
50
New
15
Increased
7
Reduced
16
Closed
10

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$24M
2
HRTX icon
Heron Therapeutics
HRTX
+$22.1M
3
PLRX icon
Pliant Therapeutics
PLRX
+$13.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.5M
5
BBIO icon
BridgeBio Pharma
BBIO
+$10.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$24M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$18.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$14.5M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.7M
5
NKTR icon
Nektar Therapeutics
NKTR
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
1
Xenon Pharmaceuticals
XENE
$6.06B
$30.7M 7.39%
850,000
-254,334
-23% -$9.14M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.9B
$28.7M 6.9%
215,000
+25,000
+13% +$3.8M
PNT
3
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$27.5M 6.63%
3,560,984
+1,140,483
+47% +$9.68M
ALPN
4
DELISTED
Alpine Immune Sciences Inc
ALPN
$24.8M 5.98%
3,448,521
+2,909,702
+540% +$24M
TVTX icon
5
Travere Therapeutics
TVTX
$5.2B
$23.8M 5.73%
966,108
-5,125
-0.5% -$132K
HRTX icon
6
Heron Therapeutics
HRTX
$93.9M
$23.5M 5.65%
+5,645,161
New +$22.1M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$22.5M 5.42%
1,551,719
+21,719
+1% +$304K
PLRX icon
8
Pliant Therapeutics
PLRX
$64.4M
$21.8M 5.24%
1,041,737
+684,474
+192% +$13.1M
RLMD icon
9
Relmada Therapeutics
RLMD
$557M
$18.9M 4.55%
510,000
-190,000
-27% -$5.26M
ACRS icon
10
Aclaris Therapeutics
ACRS
$726M
$16M 3.86%
1,019,282
-63,718
-6% -$1M
PCVX icon
11
Vaxcyte
PCVX
$7.81B
$14.4M 3.47%
600,000
-385,153
-39% -$9.76M
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$13.1M 3.15%
306,411
-53,589
-15% -$2.75M
ABOS icon
13
Acumen Pharmaceuticals
ABOS
$155M
$12M 2.9%
1,200,000
-315,000
-21% -$1.81M
ALKS icon
14
Alkermes
ALKS
$8.22B
$11.3M 2.73%
507,500
+145,864
+40% +$3.79M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$10.5M 2.52%
+76,500
New +$12.5M
BBIO icon
16
BridgeBio Pharma
BBIO
$15.7B
$10.4M 2.51%
+1,050,000
New +$10.9M
CINC
17
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$9.89M 2.38%
301,324
-367,876
-55% -$10.4M
VTYX
18
DELISTED
Ventyx Biosciences
VTYX
$9.43M 2.27%
269,967
-119,256
-31% -$2.64M
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
$9.12M 2.2%
870,000
-294,763
-25% -$3.22M
RAPT
20
DELISTED
RAPT Therapeutics
RAPT
$7.58M 1.82%
+39,375
New +$7.45M
URGN icon
21
UroGen Pharma
URGN
$1.86B
$7.27M 1.75%
873,424
– –
REPL icon
22
Replimune Group
REPL
$941M
$6.74M 1.62%
+390,000
New +$7.44M
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$10.8B
$6.21M 1.49%
+95,500
New +$6.64M
MIST icon
24
Milestone Pharmaceuticals
MIST
$138M
$6.2M 1.49%
+674,656
New +$5.12M
ETNB
25
DELISTED
89bio
ETNB
$5.53M 1.33%
955,000
-445,000
-32% -$1.96M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Great Point Partners held 50 positions worth $415M, down 0.4% from $417M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners withdrew a net $44.5M in Q3 2022, closing 10 positions and reducing 16 holdings. Its most notable exit was Cytokinetics, an estimated $24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Heron Therapeutics worth $23.5M.

  • Great Point Partners's largest Q3 2022 buy was Heron Therapeutics: 5,645,161 shares worth $23.5M.
  • Great Point Partners added most to Alpine Immune Sciences Inc in Q3 2022, an estimated $24M increase.
  • Great Point Partners's biggest Q3 2022 reduction was Nektar Therapeutics, cutting an estimated $10.7M.
  • Great Point Partners fully exited Cytokinetics in Q3 2022, selling an estimated $24M.
  • Great Point Partners's ten largest holdings make up 57% of its $415M portfolio in Q3 2022.
  • Great Point Partners opened 15 new positions and closed 10 in Q3 2022.
  • Great Point Partners's portfolio value fell 0.4% quarter-over-quarter to $415M.

Based on Great Point Partners's 13F filing for Q3 2022, filed 14 Nov 2022.